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ABSTRACT
IMMUNOSTIMULATORY AND CELLULAR TOXIC EFFECTS
OF SINGLE-STRANDED RNA ON CANCER CELLS
by Chengwen Teng
August 2012
Whether 5'-triphosphate-single-stranded-RNA (5 '-ppp-ssRNA) is
immunostimulatory was controversial in the literature. In order to clarify the
immunostimulatory effect of 5' -ppp-ssRNA, we synthesized ssRNAs and tested the IFN-

p (interferon-beta) level and cellular toxicity of ssRNAs in SKOV3 cells. In this work, we
confirmed that 5'-ppp-ssRNA (~ 60nt) was immunostimulatory and toxic in SKOV3 cells.
5'-ppp-ssRNA (~ 60nt) led to IFN-P induction and apoptosis in SKOV3 cells. Longer 5' ppp-ssRNA tended to have a higher immunostimulatory effect and cellular toxicity than
shorter 5'-ppp-ssRNA. 5'-ppp-ssRNA was more immunostimulatory and toxic than 5'0H-ssRNA. If the incubation time of ssRNAs increased, the toxicity of ssRNAs would
increase. Higher concentrations of ssRNA tended to be more toxic than lower
concentrations of ssRNA. RIG-I (retinoic acid-inducible gene 1) plays a role in the
recognition of 5' -ppp-ssRNA. This work provides a guideline for the design of
immunostimulatory RN As which can be applied in cancer therapy.
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CHAPTER I
INTRODUCTION
Immunostimulatory RNA is a Potential Drug for Cancer Therapy

Cancer and Cancer Therapy
Cancer is a group of diseases associated with uncontrolled growth of abnormal
cells caused by mutations of proto-oncogenes and tumor suppressor genes. Cancer cells
are transformed from normal cells after a series of mutations. Cancer cells have six
features different from normal cells, which are self-sufficiency in growth signals,
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and
metastasis (Hanahan & Weinberg, 2000). Cancer is now the second leading cause of
human death with more than 10 million new cases every year (Siegel, Naishadham, &
Jemal, 2012). In order to treat cancer, researchers have developed several types of cancer
therapy.
Cancer therapy includes surgery, radiation and chemotherapy. While surgery and
radiotherapy are local treatment, chemotherapy is a systemic treatment which can act on
tissues inaccessible by local treatment. Immunostimulatory RNA is a potential drug for
chemotherapy since immunostimulatory RNA can lead to cancer cell growth inhibition
and apoptosis (Chang et al., 2011).

Immunostimulatory RNA
lmmunostimulatory RNA (RNA which can activate immune pathway) can
activate pattern recognition receptors (PRRs) and induce expression of interferon and
other inflammatory cytokines, leading to cell growth arrest and apoptosis (Akira,
Uematsu, & Takeuchi, 2006). Different RNAs have different immunostimulatory
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potential. SelfRNAs (RNAs synthesized inside the cell from the cellular genome) such as
mRNA, tRNA and rRNA cannot activate the immune pathway, while some non-self
RNAs (RNAs prepared outside the cell or viral RNAs) have immunostimulatory effect.
Among non-selfRNAs, some have higher immunostimulatory effect while others have
lower immunostimulatory effect. Our long-term goal is to get non-self RNAs with very
high immunostimulatory effect so that the non-self RNAs can kill cancer cells efficiently.
Non-self RNAs include ssRNAs and dsRNAs. This study is focused on the
immunostimulatory effect of ssRNAs because the immunostimulatory effect of ssRNAs
was not well discussed in the literature.
Non-Self RNA and Innate Immune Signaling
Non-self RNA can bind to pathogen recognition receptors (PRRs) and activate
innate immune signaling pathway, leading to cytokine secretion (infereron, interleukin,
and tumor necrosis factor), cell proliferation inhibition, apoptosis and necrosis (Akira et
al., 2006). There are three main kinds of PRRs in human cells which can recognize
pathogen-associated molecular patterns (PAMPs) including non-self RNA. They are Tolllike receptors (TLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs)
(Akira et al., 2006). In addition, protein kinase R (PKR) can also recognize non-self RNA
and activate innate immune pathway (Manche, Green, Schmedt, & Mathews, 1992). In
the following section, these receptors will be discussed one by one.
Toll-like Receptors
TLRs are type I transmembrane proteins expressed either on the cell surface or
associated with intracellular vesicles (Kawai & Akira, 2011). Twelve functional TLRs
have been identified in human cells. Each TLR detects different P AMPs derived from
viruses, bacteria, mycobacteria, fungi, and parasites. These include lipoproteins
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(recognized by TLRl, TLR2, and TLR6), double-stranded (ds) RNA (TLR3),
lipopolysaccharide (LPS) (TLR4), flagellin (TLR5), single-stranded (ss) RNA (TLR7 and
TLR8), and DNA (TLR9) (Kawai et al., 2011; Manche et al., 1992). TLRs contain an
extracellular domain characterized by leucine-rich repeats (LRRs), a single
transmembrane domain, and an intracellular signaling domain known as the
Toll/interleukin-I receptor (TIR) domain (Seth, Sun, & Chen, 2006). The intracellular
TIR domain recruits downstream signaling molecules and induces cytokines and IFNs
through NF-KB (nuclear factor kappa-light-chain-enhancer of activated B cells) and IRFs
(interferon regulatory factors) (Seth et al., 2006). Since TLR3, TLR7 and TLR8 are
receptors of non-self RNA, they will be discussed in the following section.
TLR3
Double-stranded RNA can activate TLR3, leading to activation of NF-KB and
type I interferons (Alexopoulou, Holt, Medzhitov, & Flavell, 2001). When TLR3 is
activated, it recruits the adaptor protein TRIF (TIR-domain-containing adapter-inducing
interferon-~) (Oshiumi, Matsumoto, Funami, Akazawa, & Seya, 2003). Then TRIF
recruits the kinases receptor interacting proteins RIP-I and RIP-3. RIPl mediates TRIFinduced NF-KB activation (Meylan et al., 2004). In addition, TRIF can activate TBKI
(TANK binding kinase 1) via TRAF3 (TNF receptor-associated factor 3) (Hacker et al.,
2006; Oganesyan et al., 2006). Activated TBKI and IKKe (IKB kinase e) will
phosphorylate IRF3 (interferon regulatory factor 3) and IRF7 (Fitzgerald et al. , 2003;
Sharma et al., 2003). Then phosphorylated IRF-3 and IRF-7 form homodimers,
translocate into the nucleus, and bind to the promoter of type I interferon, resulting in the
expression of type I interferon (Akira et al., 2006). The ectodomains (ECDs) ofTLR3
bind dsRNA only at acidic pH (de Bouteiller et al., 2005; Leonard et al., 2008), reflecting
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TLR3's endosomal location in most cell types (Matsumoto et al., 2003). The minimal
length of dsRNA to activate TLR3 is 40 to 50 base pairs (Liu et al., 2008). Besides
dsRNA, mRNA and in vitro transcribed ssRNA can also activate TLR3 signaling (Karik6,
Ni, Capodici, Lamphier, & Weissman, 2004). TLR3 is expressed in SKOV3 cell line
(Zhou et al., 2009).

TLR7 andTLR8
The TLR7 and TLR8 genes show high homology to each other so they are
.,, ,

discussed together. Murine TLR7 and human TLR8 recognize uridine-rich or
uridine/guanosine-rich ssRNA (Diebold, Kaisho, Hemmi, Akira, & Reis e Sousa, 2004;
Heil et al., 2004). TLR7 and TLR8 are located within the endosomal membrane (Akira et
al., 2006). After ligand binding, TLR7/8 activates adaptor protein MyD88 (Myeloid
differentiation primary response gene 88). Then MyD88 recruits the interleukin-I
receptor associated kinases IRAK4, IRAKl, IRAK2 and IRAK-M (Kawai & Akira,
2010). IRAKs have an essential role in activation of NF-KB and MAPK (mitogenactivated protein kinase) (Kawagoe et al., 2008). In addition, IRAKl and/or IKKa. can
phophorylate and activate IRF7. Activated NF-KB and IRF7 will translocate into nucleus
and initiate expression of interferon and inflammatory cytokines (Kawai & Akira, 2010).
TLR7 and TLR8 are mainly expressed in pDCs. However, they are not expressed in
SKOV-3 cell line (Zhou et al., 2009).

NOD-like Receptors
NOD-like receptors (NLRs) are cytoplasmic PRRs involved in regulation of
inflammatory and apoptotic responses. NOD stands for nucleotide oligomerization
domain, and is also named as NACHT domain. NLRs typically contain a central NACHT
domain, N-terminal effector domains for binding downstream signaling molecules and a
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C-terminal receptor domain characterized by a series of leucine-rich repeats (LRRs)
(Proell, Riedl, Fritz, Rojas & Schwarzenbacher, 2008). NLR family can be divided into
four subfamilies: NLRA, NLRB, NLRC and NLRP (Kersse, Bertrand, Lamkanfi, &
Vandenabeele, 2011). Among NLR family members, NALP3 (also known as NLRP3,
cryopyrin) is involved in non-self RNA binding (Kanneganti et al., 2006a; Kanneganti et
al., 2006b). NALP3 can be activated by bacterial RNA and double-stranded RNA
(Kanneganti et al., 2006a; Kanneganti et al., 2006b ). After activation, NALP3 recruits
ASC (apoptosis-associated speck-like protein containing a CARD), and ASC in tum
recruits caspase-1 via its CARD, leading to the activation of IL-1 p (interleukin-IP) and
IL-18 processing in macrophages (Mariathasan et al., 2004). Whether NALP3 is
expressed in SKOV3 cell line and the function ofNALP3 in cancer cells is unknown.
RIG-I-like Receptors
RLRs are expressed in most cell types (Takeuchi & Akira, 2009). There are three
members in the RLR family. They are RIG-I (retinoic acid-inducible gene 1), MDA5
(melanoma differentiation-associated protein 5) and LGP2 (laboratory of genetics and
physiology 2) (Yoneyama & Fujita, 2007). RIG-I and MDA5 have two N-terminal
caspase activation and recruitment domains (CARD), a central DEAD helicase domain
and a C-terminal repressor domain (RD) while LGP2 lacks the N-terminal CARD (Loo &
Gale, 2011). Different types ofRNAs bind to RIG-I and MDA5 and activate interferon
and other inflammatory cytokines expression (Kato et al., 2006). LGP2 is the regulator of
RIG-I- and MDA5-mediated antiviral responses (Rothenfusser et al., 2005; Satoh et al.,
2010).

CARD

CARD

CARD

CARD

-

RIG-I

MDAS
LGP2

Figure 1. Structure ofRLRs. RIG-I is composed of two CARD, a DEAD helicase domain
and a C-terminal domain. MDA5 is also composed of two CARD, a DEAD helicase
domain and a C-terminal domain. LGP2 is composed of a DEAD helicase domain and a
C-terminal domain (Loo & Gale, 2011).

LGP2
In contrast with RIG-I or MDA5 , LGP2 lacks caspase activation and recruitment
domains. LGP2 binds double-stranded, but not single-stranded RNA. The regulatory
domain of LGP2 senses double-stranded RNA (Pippig et al. , 2009). The function of
LGP2 in antiviral signaling is controversial in the literature. Rothenfusser et al. (2005)
reported that LGP2 acts as a negative feedback regulator of antiviral signaling by
sequestering dsRNA from RIG-I. However, Satoh et al. (2010) proposed that LGP2 is a
positive regulator of RIG-I- and MDA5-mediated antiviral responses. To conclude, LGP2
has both positive and negative regulatory functions in immune response.

MDA-5
RIG-I and MDA5 recognize distinct RNAs, leading to the production of
interferon (Kato et al., 2008). Both RIG-I and MDA5 share several structural similarities
including the composition of three distinct domains: (1) an N-terminal region consisting
of tandem CARD; (2) a central DEAD helicase domain; and (3) a C-terminal repressor
domain (RD) embedded within the C-terminal domain (CTD) (Loo & Gale, 2011).
MDA5 preferentially recognizes poly (I:C) (polyinosinic-polycytidylic acid) and long
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dsRNA while RIG-I prefers short dsRNA and ssRNA (Kato et al., 2008). The
downstream signaling pathway ofMDA5 and subsequent cellular effect ofMDA5
activation are the same as those of RIG-I.

RIG-I
RIG-I is the best studied RLR. It is a protein of925 amino acids (Liu & Gu, 2011).
RIG-I is a cytosolic sensor of non-self RNA and is important in the induction of
interferon (Lu et al., 2010). RIG-I is broadly expressed in most tissues and cell types, and
the expression level of RIG-I is at low levels in resting cells but is largely increased with
interferon exposure and after virus infection (Loo & Gale, 2011). Because of RIG-I's
nearly universal expression and importance in non-self RNA recognition, RIG-I will be
the focus of the literature review.

Mechanism ofRIG-I Activation
RIG-I activation is composed of several steps of conformational change and
ubiquitination. When RIG-I does not bind to the ligand, it is in an autorepressed state. In
this state, RIG-I CARD2 binds to the helicase insertion domain, leading to the inhibition
of both ligand binding and ubiquitination of RIG-I. When 5'-ppp-dsRNA is present, it
will bind to CTD, leading to co-operative tight binding of ATP and RNA to the helicase.
Once RNA and ATP are bound, a conformational change in RIG-I releases CARD for
ubiquitination. In the last step, CARD is ubiquitinated, recruiting downstream VISA
(virus-induced signaling adaptor) for signal transduction (Kowalinski et al., 2011).

RIG-I-Interferon Signaling Pathway
The signaling pathway from RIG-I activation to interferon expression includes
several signaling proteins. After non-self RNA binds to RIG-I, RIG-I recruits the
downstream adaptor protein VISA (virus-induced signaling adaptor, also known as IPS-1,
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MAVS and Cardif) (Kawai et al., 2005; Meylan et al., 2005; Seth, Sun, Ea, & Chen, 2005;
Sun et al., 2006; Xu et al., 2005). VISA contains an N-terminal CARD domain and a Cterminal transmembrane domain. The CARD domain of VISA interacts with the CARD
domains of RIG-I while the transmembrane domain targets VISA to the mitochondrial
outer membrane. After VISA is activated, VISA recruits IKK complex and TBKl/lKKs.
IKK phosphorylates IKBa, leading to release of NF-KB from IKBa and translocation of
NF-KB from the cytosol to the nucleus. TBKl /lKKs phosphorylates IRF3, leading to
translocation oflRF3 from the cytosol to the nucleus. NF-KB and IRF3 bind to the
promoter oflFN-P and start the transcription ofIFN-P (Seth et al., 2006). Type I IFNs
activate the JAK-STAT signal transduction pathways, leading to transcriptional induction
of a wide range of downstream antiviral genes and, subsequently, the innate antiviral
response (Mao et al., 2010).
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Non-self RNA

RIG-I

TBKl/lKKe

..--~ IFNl3
Nucleus

Figure 2. RIG-I-Interferon signaling pathway. After non-self RNA binds to RIG-I, RIG-I
recruits downstream adaptor protein VISA. VISA recruits IKK complex and TBKl /IKKc.
IKK phosphorylates IKBa, leading to release of NF-KB from IKBa and translocation of
NF-KB from cytosol to nucleus. TBKl/IKKc phosphorylates IRF3, leading to
translocation oflRF3 from cytosol to nucleus. NF-KB and IRF3 bind to the promoter of
IFN-~ and start the transcription of IFN-~ (Seth et al., 2006).
Preference ofRIG-Ifor Different RNAs with Different Structural Features

Not all RNAs can activate RIG-I. For example, mRNA, rRNA and tRNA in the
cytosol cannot activate RIG-I. However, non-self RNA from viral infection or
transfection can activate RIG-I and the downstream immune signaling pathway.
Therefore, RIG-I can discriminate between self and non-self RNA by structural features.
These structural features include 5 '-end, single-stranded or double-stranded, length,
blunt-ended I 5' or 3' overhang and sequence motif.
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5'-End

Hornung et al. (2006) proposed that RNA containing a 5' -triphosphate was the
ligand of RIG-I. In vitro transcribed 19-nt 5' -ppp-ssRNA could induce strong interferona. production in monocytes while chemically synthesized 19-nt 5 '-OH-ssRNA could not.

If the 5'-triphosphate group was modified by either capping of the 5'-triphosphate end or
nucleoside modification, interferon-a. induction would decrease significantly. In vitro
binding assays indicated that 5'-triphosphate RNA directly bound to full-length RIG-I.
7SL RNA (signal recognition particle RNA) has a 5' -triphophate group and is present at
high copy numbers in the cytosol but it is self-RNA and is not immunostimulatory.
Therefore, 5' -triphophate may not be the only structural feature responsible for the
immunostimulatory effect (Hornung et al., 2006).
Pichlmair et al. (2006) concluded that 5' -triphosphate ssRNA could induce RIG-I
mediated immune response. RIG-I could directly bind to the influenza 5' -ppp-ssRNA
genome. Removal of 5'-triphosphate by calf intestinal phosphatase abrogated RIG-I
activation. RIG-I could form a more stable complex with 5' -ppp-RNA than 5'-0H-RNA.
Pichlmair et al. also mentioned the possibility that the complex of RIG-I and ssRNA was
stabilized by the presence of intramolecular double-stranded regions, such as the
panhandle structures that were found at the ends of the influenza genome (Pichlmair et al.,
2006). Therefore, 5'-triphophate itself may be not sufficient to induce strong RIG-I
activation.
Plumet et al. (2007) discovered that 5'-triphosphate-ssRNA, which was the viral
leader transcript of measles virus, was an activator of the RIG-I-mediated interferon
response. The 5 '-triphosphate end was required for optimal induction of interferon-~.
RIG-I was required for sensing 5' -triphosphate-RNA. The RIG-I affinity for 5' -
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triphosphate and 5' -monophosphate RNA was similar, but 5' -triphophate RNA had a
higher RIG-I activation potential (Plumet et al., 2007).
After the 5' -triphosphate RNA as an RIG-I ligand was discovered, researchers
have been investigating RIG-I's structure to explain the phenomenon. Cui et al. (2008)
discovered that the C-terminal regulatory domain (RD) was the RNA 5 '-triphosphate
sensor of RIG-I. The RD of RIG-I could bind 5'-triphosphate-RNA but not 5'-0H-RNA
(Cui et al., 2008). Lu et al. (2010) further discussed the structural basis of the binding
between the RD of RIG-I and 5'-triphosphate double-stranded RNA. Both 14-bp 5'-ppp
dsRNAand 14-bp 5'-0H dsRNAcould bind to the RD of RIG-I and form a stable
complex. However, 14-bp 5' -ppp dsRNA had higher affinity with the RD of RIG-I than
14-bp 5'-0H dsRNA. The RD of RIG-I interacted with 5'-ppp-dsRNAprimarily through
extensive electrostatic interactions with the 5'-triphosphate group and the phosphodiester
backbone. Since the a.- and P-phosphates made major contributions to the recognition of
the 5' -ppp by RIG-I, 5' -monophosphate-dsRNA and 5'-diphosphate-dsRNA could also
be ligand for RIG-I (Lu et al., 2010).
In general, a 5 '-triphophate group is a very important structural feature of RNA as
a RIG-I ligand. 5'-Monophosphate-ssRNA, 5' -diphosphate-ssRNA and 5' -0H-ssRNA
showed no interferon-a. induction potential in human monocytes and mouse embryonic
fibroblasts (Schlee et al., 2009a). However, dsRNA can still be recognized by RIG-I even
though it does not have a 5' -triphosphate group. Therefore, the 5' -triphosphate is
important for RIG-I activation, but it is not required for RIG-I activation.
Single-Stranded RNA and Double-Stranded RNA

Kim et al. (2004) concluded that siRNA and ssRNA synthesized by in vitro
transcription could induce interferon-a. and interferon-p. Yoneyama et al. (2004) stated
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that RIG-I had an essential role in double-stranded-RNA-induced immune response.
Hornung et al. (2006) discovered that in vitro transcribed 5' -ppp-ssRNA could induce
interferon-a. Pichlmair et al. (2006) concluded that RIG-I was a sensor of 5' -ppp-ssRNA
and mediated immune response. Summarizing the above papers, it seems that both
dsRNAand 5'-ppp-ssRNAcan activate RIG-I.
Schlee et al. (2009b) discovered that chemically synthetic 24-nt 5'-ppp-ssRNA
could not induce interferon-a while in vitro transcribed 24-nt 5' -ppp-ssRNA could lead to
interferon-a induction. They observed that in vitro transcribed product was not pure via
gel analysis. It has been reported that during in vitro transcription, RNA-templatedependent RNA transcription could lead to complementary double-stranded RNA
products that were originally designed to be single stranded (Cazenave & Uhlenbeck,
1994; Triana-Alonso, Dabrowski, Wadzack, & Nierhaus, 1995). It was the base-paired
side products of in vitro transcription that activated interferon-a while the main product,
5 ' -ppp-ssRNA, could not induce interferon-a (Schlee et al., 2009b ).
Schmidt et al. (2009) concluded that 5'-triphosphate RNA required base-paired
structures to activate RIG-I. In vitro transcribed RNAs contained unexpected hairpinforming double-stranded by-products that activated RIG-I. Chemically synthetic 5'-pppdsRNA could lead to interferon induction while 5 '-ppp-ssRNA could not. Besides,
double-stranded RNA could lead to RIG-I dimerization while single-stranded RNA could
not. It was the helicase domain of RIG-I that helped the RIG-I-dsRNA binding (Schmidt
et al., 2009).

It was generally accepted that dsRNA has much higher immunostimulatory
potency than ssRNA. Afterwards researchers were working on the structural basis of this
phenomenon. Takahasi et al. (2008) discovered that CTD of RIG-I recognized dsRNA.
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CTD contains a surface enriched with basic amino acids that is critical for the recognition
of dsRNA. Lu et al. (2010) further discussed the relationship between CTD of RIG-I and
RNA. Both 14-bp 5' -ppp-dsRNAand 13-nt 5' -ppp-ssRNAcould bind to CTD of RIG-I,
and dsRNA had a higher affinity than ssRNA. Three groups of amino acid residues of
RIG-I are involved in RNA binding. 5'-triphosphate group of RIG-I is recognized by the
first group of residues. The phosphate backbone of the dsRNA interacts with the second
group of residues. The third group of residues interacts with the exposed bases at the
,

'

termini of the RNA or the backbone of the RNA by hydrogen bonds. Therefore, RIG-I
can recognize both 5' -ppp-dsRNA and 5'-ppp-ssRNA (Lu et al., 2010).
Evidence of immunostimulatory potency of 5' -ppp-ssRNA includes a discovery
made by Rehwinkel et al. (2010). The viral genomic RNA of negative-stranded RNA
virus, which is 5'-ppp-ssRNA, can activate RIG-I and immune response. However,
single-stranded RNA may also have base-paring structure. Flu (influenza) and SeV
(Sendai virus) genomic RNA adopt a "panhandle" conformation by pairing of
complementary 5' and 3' ends (Rehwinkel et al., 2010). Therefore, base paring structure
contributes to the immunostimulatory potency of 5 '-ppp-ssRNA.
To conclude, researchers agreed that dsRNA can activate RIG-I but they had
different opinions about whether ssRNA can activate RIG-I. It is generally accepted that
dsRNA has higher immunostimulatory potency than ssRNA. In addition, the base-pairing
structure of RNA increases RNA's RIG-I activation potency.
RNA Length

The immunostimulatory potency of RIG-I is related with the length of RNA. As
an efficient ligand for RIG-I, RNA cannot be too short (< lObp) or too long (>3kbp). First
of all, if RNA is too short, it cannot activate RIG-I and immune signaling pathway.
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Hornung et al. (2006) discovered that in vitro transcribed 5' -ppp-ssRNA must have a
minimal length of 19 bases if the RNA could efficiently induce IFN-a in monocytes.
Schmidt et al. (2009) concluded that RNAs which could activate RIG-I must have long
enough base-pair stretches. When 5-, 10-, or 15-nt complementary RNA was hybridized
to the 5'-end of 19-nt 5'-ppp-ssRNA, RNAs with IO-base-pair and 15-base-pair structure
could lead to IFN induction but RNAs with 5-base-pair structure could not (Schmidt et al.,
2009). Schlee et al. (2009b) conducted an experiment in which a 24-nt 5'-ppp-ssRNA
was annealed with complementary RNA ranging from 13 nucleotides to 24 nucleotides.
Only the annealed RNAs with a base-pair region at least 21 bp long could activate
interferon-a (Schlee et al., 2009b).
Moreover, if RNA is too long, RNA will become ligand ofMDA5 instead ofRIG-

1. Kato et al. (2006) concluded that MDA5 recognized poly (I:C), and RIG-I detected in
vitro transcribed dsRNAs. Poly (I:C) is a relatively nuclease-stable synthetic mimic of
long dsRNA (uncleaved polyI:C, 4-8 kb) (Schlee et al., 2009a). The MDA5 ligand, poly
(I:C), was converted to a RIG-I ligand after shortening of the dsRNA length by partial
digestion. The short dsRNA obtained from digestion of poly (I:C) was about 300bp long.
Although 1 kbp dsRNA-induced IFN-P was dependent on RIG-I, 2 kbp capped-dsRNA
induced IFN-P, even in RIG-I-/- cells. The production ofIFN-P in response to 3 and 4
kbp capped-dsRNA was less dependent on RIG-I, and an impairment of IFN-P
production was observed in MDA5 -/- cells (Kato et al., 2008). To conclude, short
dsRNA is the ligand for RIG-I while long dsRNA is the ligand for MDA5.
Blunt-Ended, 5 'Overhang or 3 'Overhang RNA
The end of double-stranded RN As can have a 5' overhang, a 3' overhang or blunt
ends. How the end of dsRNA influences its immunostimulatory potency was discussed in

15

several papers recently. Marques et al. (2006) discovered that the 3 ' -overhang of dsRNA
impaired its ability to activate the immune signaling pathway. Gondai, Yamaguchi,
Miyano-Kurosaki, Habu, & Takaku (2008) found that in vitro transcribed short-hairpin
RNA with GG or GGG 5 '-overhang could not induce interferon induction. The overhang
issue was further discussed by Schlee et al. (2009b). A blunt end at the 5' -triphosphate
end is optimal for RIG-I activation, while a 3' overhang at the 5' -triphosphate end
decreases activation, and any 5 ' -overhang at the 5 ' -triphosphate end abolishes the activity
(Schlee et al., 2009b ).

5'ppp

3'

3'

5'

Optimal RIG-I ligand

3'
Decreased RIG-I activity

3'

5'

5' PPP

3'
No RIG-I activity

5'
Figure 3. Effects of blunt-ended or overhanging RNA on RIG-I activation. A blunt end at
the 5'-triphosphate end is optimal for RIG-I activation, while a 3' overhang at the 5'triphosphate end decreases activation, and any 5 '-overhang at the 5 '-triphosphate end
abolishes the activity (Schlee et al., 2009b).
During the work of Lu et al. (2010), binding assays were performed to analyze
binding affinity between RNA overhangs and RIG-I CTD. The results showed that 5' ppp-dsRNA with either 3 ' or 5' overhangs retained binding to RIG-I (Lu et al., 2010).
However, Schlee et al. (2009b) discovered that there was a great difference of RIG-I
activation potency between blunt-ended, 3' -overhang and 5' -overhang RNAs. The reason
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may be that RNA molecules with overhangs are unwound by RIG-I (Takahasi et al.,
2008).

Sequence Motif
How the sequence of RNA affects RNA's immunostimulatory potency was
discussed in several papers. Saito, Owen, Jiang, Marcotrigiano, & Gale (2008) concluded
that the polyuridine motif of the HCV (hepatitis C virus) genome 3' non-translated region
was the PAMP substrate of RIG-I. One-hundred nucleotide long poly-A RNA and polyU/UC RNA equally induced IFN-P induction. When some of the nucleotides in poly-A
RNA was changed from A to G, the IFN-P induction was attenuated (Saito et al., 2008).
Also, Gondai et al. (2008) observed that if there was more G in the ssRNA, the interferon
induction would be reduced. However, Lu et al. (2010) concluded that RIG-I CTD had no
preference for specific bases within the RNA. They observed that a 14-bp GC-rich 5'ppp-dsRNA and a 12-bp AU-rich 5 '-ppp-dsRNA could both bind to RIG-I CTD. Maybe
another part of RIG-I is responsible for distinguishing different sequence motifs. To
conclude, it seems that RIG-I prefers AU-rich RN As to G-rich RNAs. Further research is
needed to confirm the conclusion.

Protein Kinase R
PKR is a 551 amino acid protein which comprises two functional domains: an Nterminal dsRNA binding domain (dsRBD) and a C-terminal kinase domain (Cole, 2007;
Sadler, 2010). The dsRBD recognizes dsRNA with no sequence preference (Stefl et al.,
2010; Wu, Henras, Chanfreau, & Feigon, 2004). In general, a 30 bp of dsRNA is needed
for minimal activation of PKR, with longer dsRNAs activating to a greater extent.
Shorter dsRNA (15-30 bp long) inhibits PKR through competitive binding (Bevilacqua
& Cech, 1996; Ucci, Kobayashi, Choi, Alexandrescu, & Cole, 2007). After binding
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dsRNA, PKR undergoes autophosphorylation reactions which activate PKR itself.
Activated PKR then phosphorylates eIF-2a. (eukaryotic initiation factor 2a.), thus
inhibiting protein synthesis (Lemaire, Anderson, Lary, & Cole, 2008). In addition, PKR
transmits signals not only to eIF-2a. and the translational machinery, but also to various
factors such as STAT, IRFl, p53, JNK and p38, as well as engaging the NF-KB pathway
(Garcia et al., 2006; Verma, Stevenson, Schwarz, Van Antwerp, & Miyamoto, 1995;
Williams, 2001). PKR is involved in NF-KB activation, therefore inducing apoptosis
(Garcia, Meurs, & Esteban, 2007).
The ligands of PKR include not only dsRNA but also 5'-triphosphate-ssRNA
(Zheng & Bevilacqua, 2004). The 5'-triphosphate group of ssRNA is indispensible in
PKR activation, because 5 '-diphosphate, 5'-monophosphate, 5 '-hydroxyl, and 7mG capcontaining ssRNAs do not activate PKR (Nallagatla et al., 2007).
Immunostimulatory RNA and Cellular Toxicity
Immunostimulatory RNA may have cytotoxic effects (Zitvogel & Kroemer, 2009).
5' -ppp-RNA can induce apoptosis in melanoma cells (Besch et al., 2009). In addition, 5' ppp-dsRNA can induce apoptosis in SKOV3 cells (Kubler et al., 2010). The cellular
toxicity of immunostimulatory RNA may be mediated by RIG-I. The apoptotic signaling
of 5' -ppp-RNA in melanoma cells is mediated by RIG-I (Besch et al., 2009). 5'-pppdsRNA can activate RIG-I in SKOV3 cells, leading to apoptosis (Kubler et al., 2010).
How does RIG-I activation lead to apoptosis? Besch et al. (2009) stated that RIG-I
mediated apoptosis is type-I interferon-independent. After RIG-I is activated, it recruits
downstream signaling protein VISA (Sun et al., 2006). VISA is an adaptor protein
associated with mitochondria (Sun et al., 2006). Apoptosis induced by 5' -ppp-RNA
involves VISA (Besch et al., 2009). RIG-I can activate the mitochondria apoptosis
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pathway through induction ofNoxa (a pro-apoptotic protein) (Besch et al., 2009). VISA
can also activate downstream signaling protein IRF3 (Seth et al., 2006). IRF3 can directly
interact with pro-apoptotic protein Bax (Bcl-2-associated X protein), leading to apoptosis
(Chattopadhyay et al., 2010). Although Besch et al. (2009) concluded that RIG-I
mediated apoptosis is independent of interferon, RIG-I induced interferon activation may
facilitate apoptosis. IFN s can activate J AK-STAT pathway, leading to the expression of a
family of proteins known as IS Gs (IFN stimulated genes) (Shuai & Liu, 2003 ). IS Gs will
activate a network of pathways, leading to cellular growth inhibition and apoptosis
(Clarke & Tyler, 2009). The interferon-independent apoptotic pathway takes shorter time
(< 24h) while the interferon-dependent apoptotic pathway takes longer time (> 24h).
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Figure 4. Immunostimulatory RNA induced apoptosis. Immunostimulatory RNA can
induce apoptosis in a short time via pro-apoptotic proteins Noxa and Bax.
Immunostimulatory RNA can induce apoptosis in a long time via IFN-P-JAK-STAT
pathway.
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CHAPTER II
OBJECTIVES AND SIGNIFICANCE
Whether ssRNA is immunostimulatory was controversial in the literature. At first,
5'-ppp-ssRNA was observed to induce IFN-a (Hornung et al., 2006). Then the
immunostimulatory effect of 5'-ppp-ssRNA was believed to be an artifact since the in
vitro transcribed ssRNA was contaminated with dsRNA (Schlee et al., 2009b). In order to
clarify the immunostimulatory effect of ssRNA, we synthesized ssRNAs by in vitro
transcription and purified ssRNAs by PAGE to remove dsRNA contamination. Then
ssRNAs were transfected into SKOV3-Luc cells to study ssRNAs' cellular toxicity and
immunostimulatory effect. We hypothesized that 5'-triphophate single-stranded RNA
could activate the immune response and led to cell death in SKOV3-Luc cells. We
expected that 5'-ppp-ssRNA was more toxic than 5'-0H-ssRNA in cancer cells because
Hornung et al. (2006) stated that 5' -ppp-ssRNA could induce IFN-a while 5'-OH-ssRNA
could not. We also expected that longer 5' -ppp-ssRNA was more toxic than shorter 5' ppp-ssRNA because Hornung et al. (2006) discovered that 5' -ppp-ssRNA generated from
in vitro transcription required a minimal length of 19 bases to efficiently induce IFN-a in
monocytes. Furthermore, we expected that RIG-I played a role in the recognition of 5'ppp-ssRNA in cancer cells because 5'-ppp-ssRNA was believed to be the ligand of RIG-I
(Hornung et al., 2006).
Objective 1: Determine How the Length and the 5' -End of ssRNAs
Affect ssRNAs' Immunostimulatory Effect and Cellular Toxicity
About a year ago, we were trying to design RNAs which have both the RNAi
effect and the immunostimulatory effect. We chose the SKOV3-Luc cell line, which is an
ovarian cancer cell line stably expressing the firefly luciferase gene, for gene knockdown
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analysis. We synthesized 145nt 5'-ppp-Luc-MSl-ssRNAand 147nt 5'-ppp-Luc-MAlssRNA targeting luciferase gene (MS stands for medium-long sense-strand RNA and MA
stands for medium-long antisense-strand RNA). We planned to study their gene
knockdown effect via luciferase assay. However, cells transfected with 5'-ppp-Luc-MSlssRNA and 5' -ppp-Luc-MAl-ssRNA quickly underwent apoptosis. Since there was
controversy about ssRNA's immunostimulatory effect in the literature (Hornung et al.,
2006; Schlee et al., 2009b ), we decided to change our research direction from studying
RNAi to clarifying this question: is ssRNA immunostimulatory? If so, how does the
structure of ssRNA affect its immunostimulatory effect? The structural features of ssRNA
include the 5'-end, length and the sequence motif. In order to study how the 5'-end of
ssRNAs affects their immunostimulatory effect, 5'-0H-Luc-MSl-ssRNA was generated
from 5' -ppp-Luc-MS 1-ssRNA via calf alkaline intestine phosphatase treatment. Then
both 5' -ppp-Luc-MSl-ssRNA and 5'-0H-Luc-MSl-ssRNA were transfected into
SKOV3-Luc cells and their cellular toxicity and immunostimulatory effect were
compared.
Luc-MS 1-ssRNA and Luc-MA 1-ssRNA have specific sequences. It is known in
the literature that the sequence of ssRNAs may affect ssRNAs' immunostimulatory effect
(Gondai et al., 2008; Saito et al., 2008). In order to get a general knowledge of ssRNAs'
immunostimulatory effect, we designed and studied random sequenced ssRNAs. Random
sequenced ssRNAs in the length of 20, 40, 60 and 80 nucleotides were synthesized via in
vitro transcription. The first two nucleotides of random sequenced ssRNAs were A and G
due to T7-phage polymerase's preference when ssRNAs were prepared via in vitro
transcription. The rest of the nucleotides of ssRNAs had equal chance to be A, U, C or G
In order to study how the length of ssRNAs affects ssRNAs' immunostimulatory effect
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and cellular toxicity, random sequenced ssRNAs in different length (20nt, 40nt, 60nt and
80nt) were transfected into SKOV3-Luc cells and then their cellular toxicity and
immunostimulatory effect were compared. In order to study how the 5' -end of ssRNAs
affect ssRNAs' immunostimulatory effect and cellular toxicity, 5'-0H-80nt-randomssRNA were generated via calf intestine alkaline phosphatase treatment of 5'-ppp-80ntrandom-ssRNA. Then both 5'-ppp-80nt-random-ssRNA and 5' -OH-80nt-random-ssRNA
were transfected into SKOV3-Luc cells and their cellular toxicity and immunostimulatory
effect were compared.
Objective 2: Determine the Role of RIG-I in the Recognition of 5'-ppp-ssRNA
After the cellular toxicity and immunostimulatory effect of ssRNA were characterized,
we were trying to find out the mechanisms involved. Since Hornung et al. (2006) stated
that RIG-I could directly bind to 5'-ppp-ssRNA, we expected that RIG-I played an
important role in the recognition of 5'-ppp-ssRNA. To confirm the hypothesis, we used
RIG-I siRNA to knock down RIG-I expression in SKOV3-Luc cells, and then 5'-ppp80nt-random-ssRNA was transfected into the cells. We expected that the cellular toxicity
and immunostimulatory effect of 5'-ppp-80nt-random-ssRNA would be attenuated if
RIG-I expression was knocked down.
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CHAPTER III
MATERIALS AND METHODS
Experimental Protocols

Double-Stranded DNA Template Synthesis and Purification
Double-stranded DNA templates were synthesized via polymerase chain reaction
(see Table 1). After dsDNA templates were synthesized, they were purified by the method
of ethanol precipitation: dsDNA templates were precipitated by adding 3 parts of
DNA/RNA precipitation buffer (see Table 2) and 7 parts of ethanol. After mixing and
incubation for 60 min at -20 °C, the sample was centrifuged for 10 min at 14,000 RPM.
Then the supernatant was removed and the pellet was dissolved in DNase/RNase-free
H20.
Table I

Polymerase Chain Reaction (500 µ/)

Reagent

Concentration

50µ1 IOx buffer

IX

50µ1 25mM MgCh

2.5mM

4µ1 25mM dNTP

0.2mM

25µl 20µM primer

lµM

lµl dsDNA template
365µ1 H20
5µ1 Taq polymerase
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The reaction was started at 94°C for 1.5 min, followed by 7 cycles of PCRs: at 94°C
for 30 s, at 54°C for 30 s, and at 72°C for I min, and the final incubation at 72°C for 5 min.
Table 2
DNA/RNA Precipitation buffer (10 ml)

Reagent

Concentration

50 µl 0.2 M EDTA

lmM

1 ml 5 MNaAc

0.5M

8.95 ml Water

5 '-ppp-ssRNA in vitro Transcription and Purification
5'-ppp-ssRNAs were synthesized via in vitro transcription (see Table 3). After 5'ppp-ssRNAs were synthesized, they underwent two steps of purification. First, they were
purified by the method of ethanol precipitation. Second, PAGE purification was
performed. 5'-ppp-ssRNAs were separated by 8% denaturing PAGE. The objective ,
sample band was visualized under ultraviolet light, cut from the gel and then transferred
into a 1.5 ml Eppendorftube. The gel was then crushed and RNA was extracted from the
gel by adding 400 µl of 0.5 M NaAc in 1 mM EDTA and heating at 70°C for 10 minutes.
The supernatant was centrifuged and transfered to a clean tube. 900 µl of ethanol was
added to the tube and the tube was incubated at -20 °C for 1 hour. Then the tube was
centrifuged for 10 min at 14,000 RPM. The supernatant was removed and the pellet was
dissolved in DNase/RNase-free H20.
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Table 3

High Yield T7 RNA Transcription (100 µI)

Concentration

Reagent

10 µl 1OX T7 buffer

IX

10 µl 0.1 M DTT

lOmM

30 µl 25 mM NTPs

0.75 mM

5 µl 4 µM DNA template

0.2µM

10 µl AmpliScribe Enzyme Solution

10% v/v

35 µl water

Table 4

Denaturing Gel Running Dye (10 ml)

Reagent

Concentration

4.2 g Urea

7M

1 mL lOX TBE buffer

IX

Bromophenol blue

0.05%

Xylene Cyanole

0.05%

4 mL Water
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Table 5

Denaturing Gel Mix (] L)

Reagent

Concentration

420 g Urea

7M

100 ml 1OX TBE buffer

IX

200 ml 40% Bis-acrylamide (19:1)

8%

Add water to I L

5 '-OH-ssRNA Preparation and Purification
5' -OH-ssRNAs were prepared via calf intestine phosphatase treatment of 5'-pppssRNA (see Table 6). Then 5'-0H-ssRNAs were purified via ethanol precipitation and
followed by PAGE purification.
Table 6

Calf Intestine Alkaline Phosphatase Treatment (50 µ/)

Reagent

Concentration

29µ1 Water
12µ15'-ppp-ssRNA
5 µl 10 x buffer

IX

4µ1 Calf intestinal alkaline phosphatase

The sample was incubated at 3 7 °C for 4 hours.
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Cell Culture

SKOV3-Luc cells were cultured in folate-free RPMI 1640 (Gibco) medium
supplemented with 10% fetal calf serum (FCS) (HyClone), 100 units/mL penicillin, and
100 µg/mL streptomycin (Millipore) at 3 7 °C in 95% air humidified atmosphere and 5%

CO2.
Transfection

RNAs were transfected into SKOV3-Luc cells via Dharmafect transfection
reagent according to manufacturer's protocol. SKOV3-Luc cells were plated into the
plate 24 hours prior to transfection. The cells reached about 30% confluence before
transfection. The final concentration of Dharmafect transfection reagent in the medium
was 1/250.
Determination ofRelative Cell Number by Spectrophotometry

We used a spectrophotometer to analyze the relative cell number because the
blanked absorbance measured by the spectrophotometer was proportional to relative cell
number of the cells. The cells were stained with Toluidine blue, which has a maximum
peak absorbance at a wavelength of 630nm. The amount of light that each sample
absorbed indicated the amount of stained cells. This method had several steps. First, cells
(cultured in a 48-well plate) were fixed with 300µ1/well of methanol for 10 minutes at
room temperature. Second, the methanol was removed and the plate was allowed to dry at
room temperature for 5 minutes. Third, 300µ1/well of Toluidine Blue (TB) solution was
added to cover the cells for 20 minutes at room temperature. Fourth, the plates were
washed twice with water for 30 seconds. Fifth, TB was extracted using 300µ1/well of2%
sodium dodecyl sulfate (SDS). Sixth, 2% SDS was added into an empty well to be used
as a blank so that the absorbance of light by SDS in each of the sample could be
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subtracted. In the last step, the absorbance level at 630nm was determined with a BIOTEK ELX-800 plate reader using KC Junior Software.
Total RNA Extraction
Adhesive SKOV3-Luc cells were washed with PBS once before being lysed in
TRI reagent (Sigma-Aldrich) by pipetting. 0.5 ml of TRI reagent was added to each well
(6-well plate). The homogenized samples were incubated for 5 min at room temperature
to permit complete lysis. The samples were transferred into tubes. Chloroform was added
in a volume which is 1/5 of the volume of TRI reagent. The samples were shaken for 2
minutes by vortex mixer and were incubated at room temperature for 5 minutes. Then the
samples were centrifuged at 12,000 x g for 15 minutes. Following centrifugation, the
mixture separated into a lower red, phenol-chloroform phase, an interphase, and a
colorless upper aqueous phase. RNA remained exclusively in the aqueous phase. The
upper aqueous phase was transferred carefully to a new tube. The RNA was precipitated
from the aqueous phase by mixing with isopropyl alcohol (use 0.25 ml of isopropyl
alcohol per 0.5 ml of TRI reagent). The samples were incubated at room temperature for
10 minutes and were centrifuged at 12,000 x g for 10 min. The supernatant was removed.
The RNA pellet was washed once with 1ml of75% ethanol. The tube was shaken and
centrifuged at 7,500 x g for 5 min. The RNA pellet was dried briefly and was dissolved in
DNase/RNase-free H20. RNA was quantitated by absorbance at 260nm. The quality of
the extracted RNA was evaluated by A260/A2so ratio.
Gene Expression Analysis by Real-Time PCR
Total RNA was extracted from SKOV3-Luc cells with TRI reagent following the
manufacturer's protocol and mRNAs were converted to cDNA through reverse
transcription with MMLV reverse transcriptase (Promega) (see Table 7). Finally, real-
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time PCR was performed with on MX3000P (Stratagene) (see Table 8). The mRNA level
from real-time PCR was calculated using the comparative Ct method (Pfaffl, 2001). ~Actin mRNA was used as a calibrator for the calculation ofrelative mRNA levels of the
tested genes.
Table 7
Reverse Transcription (20 µ/)

Reagent

Concentration

4 µl 5X RT Buffer

IX

0.8 µl 25 mM dNTPs

lmM

0.4 µl 50 µM Primers

lµM

1 µl 1 µM Total RNA

50nM

1 µl of 1Ou/µl MML V reverse transcriptase

0.5 u/ µl

12.8 µl water

The sample was incubated at 70 °C for 5 min. Then the sample was cooled down.
4 µl 5X RT buffer and 1 µl of lOu/µl MMLV reverse transcriptase were added to the
sample. Then the sample was incubated at 42 °C for 1 h.
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Table 8

Real-Time PCR (20 µl)

Reagent

Concentration

10 µl 2X SYBR Solution

IX

2 µl 2 µM Primers

0.2 µM

0.2 µlcDNA
7.8 µl Water

The reaction was started at 95°C for 10 min, followed by 40 cycles of PCRs: at 95°C
for 15 s, at 60°C for 30 s, and at 72°C for 30 s, and one more cycle of PCR: at 95°C for 45 s,
at 70°C for 30 s, and at 95°C for 30 s.

Statistical Analysis
Analysis of the statistical significance of relative cell number was performed by
Microsoft Excel software using the student's t test. Before measuring relative cell number
by spectrophotometry, each group of treatments were repeated 3 times to ensure accuracy
of results.
DNA and RNA Sequence
Luc-MS 1-ssRNA sequence:
AGGUGUUGGGCGCGUUAUUUAUCGGAGUUGCAGUUGCGCCCGCGAACGAC
AUUUAUAAUGAACGUGAAUUGCUCAACAGUAUGGGCAUUUCGCAGCCUAC
CGUGGUGUUCGUUUCCAAAAAGGGGUUGCAAAAAAUUUUGAACGU
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Luc-MAl-ssRNA sequence:
AGGACGUUCAAAAUUUUUUGCAACCCCUUUUUGGAAACGAACACCACGGU
AGGCUGCGAAAUGCCCAUACUGUUGAGCAAUUCACGUUCAUUAUAAAUGU
CGUUCGCGGGCGCAACUGCAACUCCGAUAAAUAACGCGCCCAACACC
20nt-random-ssRNA sequence: AG(N)1s
40nt-random-ssRNA sequence: AG(N)3s
60nt-random-ssRNA sequence: AG(N)ss
80nt-random-ssRNA sequence: AG(N)78
dsDNA template sequence for in vitro transcription ofLuc-MS1-ssRNA:
CGTAATACGACTCACTATAGGTGTTGGGCGCGTTATTTATCGGAGTTGCAGTT
GCGCCCGCGAACGACATTTATAATGAACGTGAATTGCTCAACAGTATGGGCA
TTTCGCAGCCTACCGTGGTGTTCGTTTCCAAAAAGGGGTTGCAAAAAATTTTG
AACGT
dsDNA template sequence for in vitro transcription ofLuc-MAl-ssRNA:
CGTAATACGACTCACTATTAGGACGTTCAAAATTTTTTGCAACCCCTTTTTGG
AAACGAACACCACGGTAGGCTGCGAAATGCCCATACTGTTGAGCAATTCACG
TTCATTATAAATGTCGTTCGCGGGCGCAACTGCAACTCCGATAAATAACGCG
CCCAACA CC
dsDNA template sequence for in vitro transcription of20nt-random-ssRNA:
CGTAATACGACTCACTATTAG(N)1s
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dsDNA template sequence for in vitro transcription of 40nt-random-ssRNA:
CGTAATACGACTCACTATTAG(N)Js

dsDNA template sequence for in vitro transcription of 60nt-random-ssRNA:
CGTAATACGACTCACTATTAG(N)ss

dsDNA template sequence for in vitro transcription of 80nt-random-ssRNA:
CGTAATACGACTCACTATTAG(N)?S

Primers' sequence for PCR of dsDNA template sequence for in vitro transcription of
Luc-MS 1-ssRNA:
Forward primer: CGTAATACGACTCACTATAGGTGTTGGGCGCGTTATITA
Reverse primer: ACGTTCAAAATTTTTTGCAA

Primers' sequence for PCR of dsDNA template sequence for in vitro transcription of
Luc-MS 1-ssRNA:
Forward primer: CGTAATACGACTCACTATTAGGACGTTCAAAATTTTTTGCAA
Reverse primer: GGTGTTGGGCGCGTTATTTA

Primers' sequence for PCR of dsDNA template for in vitro transcription of 20nt-randomssRNA:
Primer 1: CGTAATACGACTCACTATTAG(N),s
Primer 2: CTAATAGTGAGTCGTATTACG

Primers' sequence for PCR of dsDNA template for in vitro transcription of 40nt-randomssRNA:
Primer 1: CGTAATACGACTCACTATTAG(N)3s
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Primer 2: CTAATAGTGAGTCGTATTACG

Primers' sequence for PCR of dsDNA template for in vitro transcription of 60nt-randomssRNA:
Primer 1: CGTAATACGACTCACTATTAG(N)ss
Primer 2: CTAATAGTGAGTCGTATTACG

Primers' sequence for PCR of dsDNA template for in vitro transcription of 80nt-randomssRNA:
Primer 1: CGTAATACGACTCACTATTAG(N)?s
Primer 2: CTAATAGTGAGTCGTATTACG

Primers for real-time PCR of P-actin:
Forward primer: CATGTACGTTGCTATCCAGGC
Reverse primer: CTCCITAATGTCACGCACGAT

Primers for real-time PCR ofIFN-P:
Forward primer: CAAGTGTCTCCTCCAAAT
Reverse primer: CAGGGATGTCAAAGITCA

Primers for real-time PCR of RIG-I:
Forward primer: GCATA ITGACTGGACGTGGCA
Reverse primer: CAGTCATGGCTGCAGITCTGTC

The sequence of DNA oligonucleotide for the in vitro transcription of sense strand of
RIG-I siRNA
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RIG-Isl CGTAATACGACTCACTATTAGGCATITCT
RIG-I s2 AGATGCGGTGTTGCTCCAGAAATGCCTAATAGTGAGTCGTATTACG
Anneal RIG-Isl and RIG-I s2 to form dsDNA template for the in vitro transcription of
sense strand of RIG-I siRNA

The sequence of DNA oligonucleotide for the in vitro transcription of antisense strand of
RIG-I siRNA
RIG-I al CGTAATACGACTCACTATTAGGAGATGCG
RIG-I a2 AAAGGCATTTCTGGAGCAACACCGCATCTCCTAATAGTGAGTCGTAT
TACG
Anneal RIG-I al and RIG-I a2 to form dsDNA template for the in vitro transcription of
antisense strand of RIG-I siRNA

Sense strand sequence of RIG-I siRNA:
AGGCAUUUCUGGAGCAACACCGCAUCU

Antiense strand sequence of RIG-I siRNA:
AGGAGAUGCGGUGUUGCUCCAGAAAUGCCUUU
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CHAPTER IV
RESULTS
Characterization of dsDNA Templates for in vitro Transcription
Double-stranded DNA templates for in vitro transcription of 20nt-random-ssRNA,
40nt-random-ssRNA, 60nt-random-ssRNA, 80nt-random-ssRNA, Luc-MS 1-ssRNA and
Luc-MAl-ssRNA were synthesized via polymerase chain reaction and purified by
ethanol precipitation. These dsDNA templates were loaded onto polyacrylamide gel and
electrophoresis was ·p erformed. Then the gel was stained with ethidium bromide and
photos were taken under ultraviolet light.

20nt

40nt

60nt

80nt

MS 1

IV1A 1

Figure 5. Gel electrophoresis of dsDNA templates for in vitro transcription. From left to
right were the dsDNA templates for in vitro transcription of 20nt-random-ssRNA, 40ntrandom-ssRNA, 60nt-random-ssRNA, 80nt-random-ssRNA, Luc-MS 1-ssRNA and LucMAl-ssRNA.
The dsDNA templates were very pure and most of them showed single band in
PAGE. The MS 1 dsDNA template showed two bands. The upper band was MS 1 dsDNA
while the lower band was the PCR primer when MS 1 dsDNA template was synthesized.
The purity of dsDNA templates was acceptable for the following in vitro transcription
experiments.
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Characterization of ssRNAs
5 ' -ppp-20nt-random-ssRNA, 5 ' -ppp-40nt-random-ssRNA, 5 ' -ppp-60nt-randomssRNA, 5'-ppp-80nt-random-ssRNA, 5'-ppp-Luc-MSl-ssRNA and 5'-ppp-Luc-MAlssRNA were synthesized via in vitro transcription using above dsDNA templates and
were purified by ethanol precipitation and gel purification. 5' -OH-80nt-random-ssRNA
and 5' -0H-Luc-MS 1-ssRNA were prepared via calf intestine alkaline phophatase
treatment of 5' -ppp-80nt-random-ssRNA and 5 ' -ppp-Luc-MS 1-ssRNA, respectively and
were purified by ethanol precipitation and gel purification. These ssRNAs were loaded
onto polyacrylamide gel and electrophoresis was performed. Then the gel was stained
with ethidium bromide and photos were taken under ultraviolet light.
3p-20nt 3p-40nt 3p-60nt 3p-80nt OH-80nt

3p-MS I

OH-MS!

3p-MAI

Figure 6. Gel electrophoresis of ssRNAs. From left to right were 5 '-ppp-20nt-randomssRNA, 5 ' -ppp-40nt-random-ssRNA, 5' -ppp-60nt-random-ssRNA, 5 ' -ppp-80nt-randomssRNA, 5'-0H-80nt-random-ssRNA, 5'-ppp-Luc-MSl-ssRNA, 5'-0H-Luc-MSI-ssRNA
and 5'-ppp-Luc-MAl-ssRNA.
These ssRNAs were very pure since they showed a single band in PAGE. The
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purity of ssRNA is crucial for cellular study because in vitro transcribed ssRNAs may be
contaminated with dsRNA by-products and the dsRNA contamination will affect the
sample's immunostimulatory effect (Schlee et al., 2009b). Since the ssRNAs were quite
pure, they could be used in the following cellular study.
Effects of ssRNAs on Cell Morphology and Viability
SKOV3-Luc cells were treated with 500µg/l of 5' -ppp-20nt-random-ssRNA, 5'ppp-40nt-random-ssRNA, 5 ' -ppp-60nt-random-ssRNA, 5' -ppp-80nt-random-ssRNA, 5 ' OH-80nt-random-ssRNA, 5' -ppp-Luc-MSl-ssRNA, 5'-0H-Luc-MSl-ssRNA, 5'-pppLuc-MAl-ssRNA or Poly (I:C) for 24 hours with Dharmafect transfection reagent in a
48-well plate. The control cells were treated with Dharmfect transfection reagent only.
The cells were fixed and stained with Toluidine blue. Then photographs were taken under
a microscope.
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5 '-OH-80 nt-random-ssRN A

Poly(I:C)

Figure 7. The morphology of cells treated with ssRNA or Poly (I:C). SKOV3-Luc cells
were treated with ssRNA or Poly (l:C) for 24 hours with Dharmafect transfection reagent
in a 48-well plate. The control cells were treated with Dharmfect transfection reagent
only. The cells were fixed and stained with Toluidine blue. Then photographs were taken
under microscope.
The images showed that more than half of the cells were changing their shape
from spindle-like (healthy state) to round or irregular when the cells were treated with 5'-
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ppp-60nt-random-ssRNA, 5' -ppp-80nt-random-ssRNA, 5' -ppp-Luc-MS 1-ssRNA, 5'ppp-Luc-MAl-ssRNA and Poly (l:C). The cellular shape change indicated that many
cells were undergoing apoptosis. Poly (I:C) is a dsRNA mimic and is known to be
immunostimulatory and toxic so Poly (l:C) was set as a positive control. The reason for
the toxicity of 5' -ppp-ssRNAs may be related with RIG-I mediated apoptotic pathway
(Besch et al., 2009). In contrast, cells treated with 5'-0H-80nt-random-ssRNA and 5'0H-Luc-MS1-ssRNA were in a much more healthy state than cells treated with 5'-ppp80nt-random-ssRNA and 5'-ppp-Luc-MS1-ssRNA, showing that 5'-ppp-ssRNA was
more toxic than 5' -OH-ssRNA. In addition, cells treated with 5' -ppp-20nt-randomssRNA and 5'-ppp-40nt-random-ssRNA were in a much more healthy state than cells
treated with 5' -ppp-60nt-random-ssRNA and 5' -ppp-80nt-random-ssRNA, showing that
longer 5'-ppp-ssRNA was more toxic than shorter 5' -ppp-ssRNA.
Cellular Toxicity of Luc-MS 1-ssRNA and Luc-MAl-ssRNA at
Different Incubation Times
SKOV3-Luc cells were treated with the same molar concentration (20nM) of 5'ppp-Luc-MS1-ssRNA, 5'-ppp-Luc-MAl-ssRNA or 5'-0H-Luc-MS1-ssRNA for 6 hours
and 24 hours with Dharmafect transfection reagent in a 48-well plate. The control cells
were treated with Dharmfect transfection reagent only. Then the relative cell numbers
were tested via spectrophotometer.
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Figure 8. Relative cell number of cells treated with Luc-ssRNAs at different incubation
times. SKOV3-Luc cells were treated with the same molar concentration (20nM) of LucssRNA for 6 hours and 24 hours with Dharmafect transfection reagent in a 48-well plate.
The control cells were treated with Dharmfect transfection reagent only. Then the relative
cell numbers were tested via spectrophotometer.
The cells treated with 5'-ppp-Luc-MS1-ssRNA had lower cell number than those
treated with 5' -OH-Luc-MS 1-ssRNA (p<0.05), showing that the cellular toxicity of 5' ppp-Luc-MS 1-ssRNA was stronger than that of 5'-0H-Luc-MS 1-ssRNA. The reason
may be that RIG-I prefers 5' -ppp-ssRNA to 5'-0H-ssRNA, inducing stronger response
when binding to 5' -ppp-ssRNA (Hornung et al., 2006). The toxicity of 5'-0H-Luc-MSlssRNA was significant, which indicated that long 5' -0H-ssRNA (145nt) was toxic. The
cellular toxicity of 5'-ppp-Luc-MS1-ssRNA and 5'-ppp-Luc-MAl-ssRNA were similar
since they were similar in length (145nt vs. 147nt). In addition, the cellular toxicity of
Luc-ssRNA increased when the incubation time increased. The reason may be that it
takes time for cellular signal transduction in the immune and apoptotic pathways. When
the incubation time is elongated, more cells will undergo apoptosis.
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Cellular Toxicity of Luc-MS 1-ssRNA and Luc-MA 1-ssRNA in Different Concentrations
SKOV3-Luc cells were treated with different concentration (0.2nM, 2nM and
20nM) of 5'-ppp-Luc-MS1-ssRNA, 5'-ppp-Luc-MAl-ssRNA or 5'-0H-Luc-MSlssRNA for 24 hours with Dharmafect transfection reagent in a 48-well plate. The control
cells were treated with Dharmfect transfection reagent only. Then the relative cell
numbers were tested via spectrophotometer.

•0.2nM
U 2nM
a20nM

Con

5'-ppp-Luc-MS1 ·RNA 5' ·PPP· Luc-MAl ·RNA 5'-OH-Luc-MSl ·RNA

Figure 9. Relative cell number of cells treated with Luc-ssRNAs in different
concentrations. SKOV3-Luc cells were treated with different concentration (0.2nM, 2nM
and 20nM) of Luc-ssRNA for 24 hours with Dharmafect transfection reagent in a 48-well
plate. The control cells were treated with Dharmfect transfection reagent only. Then the
relative cell numbers were tested via spectrophotometer.
The cellular toxicity of 5'-ppp-Luc-MSl-ssRNA was stronger than that of 5'-0HLuc-MSl-ssRNA and the cellular toxicity of 5'-ppp-Luc-MSl-ssRNA and 5'-ppp-LucMAl-ssRNA were similar, which showed the same pattern as the previous result. The
dose-effect relationship result showed that the cellular toxicity of 5'-ppp-Luc-MS 1-RNA,
5'-ppp-Luc-MAl-RNA and 5'-0H-Luc-MS1-RNA increased when their doses increased.
The possible reason is that more ligands will bind more receptors and induce stronger
immunostimulatory effect.
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Cellular Toxicity of Random Sequenced ssRNA in Different
Lengths and Incubation Times
SKOV3-Luc cells were treated with the same mass concentration (528µg/l) of
randomly sequenced 5 ' -ppp-ssRNA of different length (20nt, 40nt, 60nt or 80nt) for 24
hours and 48 hours with Dharmafect transfection reagent in a 48-well plate. The control
cells were treated with Dharmfect transfection reagent only. Then the relative cell
numbers were tested via spectrophotometer.
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Figure 10. Relative cell number of cells treated with random sequenced ssRNA in
different lengths and incubation times. SKOV3-Luc cells were treated with the same
mass concentration (528µg/l) ofrandomly sequenced 5' -ppp-ssRNA for 24 hours and 48
hours with Dharmafect transfection reagent in a 48-well plate. The control cells were
treated with Dharmfect transfection reagent only. Then the relative cell numbers were
tested via spectrophotometer.
The cellular toxicity of random sequenced ssRNA increased when the length of
ssRNA increased from 20nt to 80nt. There was a big jump in the increase when the
length of ssRNA changed from 40nt to 60nt, indicating that the receptors of ssRNA
prefer ssRNA longer than 40nt. The receptor may be RIG-I since it is stated in the

42

literature that RIG-I can be activated by 5'-ppp-ssRNA (Hornung et al., 2006). In
addition, the cellular toxicity of random sequenced ssRNA increased when the incubation
time increased, showing the same pattern as Luc-ssRNAs.
Cellular Toxicity of Random Sequenced 5'-ppp-ssRNA and 5'-0H-ssRNA
SKOV3-Luc cells were treated with the same mass concentration (528µg/l) of 5' ppp-80nt-random-ssRNA or 5'-0H-80nt-random-ssRNA for 24 hours with Dharmafect
transfection reagent (0.8µ1 /well) in a 48-well plate. The control cells were treated with
Dharmfect transfection reagent only. Then the relative cell numbers were tested via
spectrophotometer.
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Figure 11. Relative cell number of cells treated with random sequenced 5'-ppp-ssRNA
and 5'-0H-ssRNA. SKOV3-Luc cells were treated with the same mass concentration
(528µg/l) of 80nt-random-ssRNA for 24 hours with Dharmafect transfection reagent in a
48-well plate. The control cells were treated with Dharmfect transfection reagent only.
Then the relative cell numbers were tested via spectrophotometer.
The cellular toxicity of 5'-ppp-80nt-ssRNA was stronger than that of 5'-0H-80nt-

43

ssRNA, showing the same pattern as Luc-MSl-ssRNA. It provided more evidence of the
hypothesis that 5'-ppp-ssRNA is more toxic than 5'-0H-ssRNA in cancer cells. However,
the toxicity of 5 '-OH-Luc-MS 1-ssRNA (14 7nt) was significant while 5' -ppp-80ntssRNA had little toxicity. It showed that when ssRNA was short (80nt), the toxicity of
ssRNA was dependent on 5' -triphosphate group. When ssRNA was long (145nt), the
toxicity of ssRNA was much less dependent on 5 '-triphosphate group.
IFN-P mRNA Level of Cells Treated with ssRNAs
SKOV3-Luc cells were treated with 500µg/l of 5' -ppp-20nt-random-ssRNA, 5'ppp-40nt-random-ssRNA, 5' -ppp-60nt-random-ssRNA, 5 ' -ppp-80nt-random-ssRNA, 5 ' OH-80nt-random-ssRNA, 5' -ppp-Luc-MS 1-ssRNA, 5' -OH-Luc-MS 1-ssRNA, 5' -pppLuc-MAl-ssRNA or Poly (I:C) for 12 hours with Dharmafect transfection reagent in a 6well plate. The control cells were treated with Dharmfect transfection reagent only. Then
total RNA was extracted and the IFN-P mRNA level of the cells was tested via real time
PCR.
90000

T--··-- -- - . -----···---··-______. ______

80000 t -· ...

i

-

70000 ---····-·-

____

· · · - - - - - - - ,....

- ·

·--

-

F···---------··.·--------·--·
I

GI

'

j

60000
~ 50000 · · - - - - - · -·-·-·····---·-·-

·---

er:

E 40000 T - - - - ·. ··- · - - -··
~
I
~ 30000

~--·- -~

--

---

a12h

r--··---·-·-· --- ,

- 20000
10000
0

-1-·---··-- -·-- ·---·-- ·--r·--

L_

- - ---

I ____ _

- ·· -

·· --··

,·-·-·-

_J_

Figure 12. IFN-P mRNA level of cells treated with ssRNAs. SKOV3-Luc cells were
treated with 500µg/l of ssRNA or Poly (I:C) for 12 hours with Dharmafect transfection
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reagent in a 6-well plate. The control cells were treated with Dharmfect transfection
reagent only. Then total RNA was extracted and IFN-P mRNA level of the cells was
tested via real time PCR. The control IFN-P mRNA level is set as one.
The IFN-P mRNA level of the cells treated with ssRNA showed similar pattern as
the cellular toxicity of ssRNA in cancer cells. It was indicated that longer 5 '-ppp-ssRNAs
had a higher imrnunostimulatory effect than shorter 5' -ppp-ssRNAs; 5' -ppp-ssRNAs had
a higher imrnunostimulatory effect than 5' -OH-ssRNAs. The cellular toxicity of ssRNA
also obeyed the above two rules. Therefore, ssRNA-mediated activation of immune
pathway may be related with the toxicity of ssRNA and apoptosis of cancer cells.
However, the toxicity of ssRNA was not fully correlated with the IFN-P induction of
ssRNA. The IFN-P mRNA level difference between 5'-ppp-Luc-MSl-ssRNA and 5' 0H-Luc-MSl-ssRNA was significant while the toxicity difference between 5'-ppp-LucMSl-ssRNA and 5' -0H-Luc-MS1-ssRNA was much less significant. It showed that
different pathways were involved between IFN-P induction and cellular toxicity. The
IFN-P induction is mediated by a pathway which consists of signaling proteins such as
RIG-I, VISA, IKKs, NF-KB, TBKl and IRF3 (Seth et al., 2006). The cellular toxicity is
mediated by a pathway which is composed of signaling proteins such as RIG-I, VISA,
IRF3 , Noxa and Bax (Besch et al. , 2009; Chattopadhyay et al., 2010).
RIG-I Plays a Role in the Recognition of 5'-ppp-ssRNA.
In order to study the role of RIG-I in the recognition of 5'-ppp-ssRNA, SKOV3Luc cells were first transfected with RIG-I siRNA and then were transfected with 5' -ppp80nt-random-ssRNA. The control SKOV3-Luc cells (first group) were treated with
Dharmafect transfection reagent for 24 hours, and then the medium was changed and the
control cells were treated with Dharmafect transfection reagent for another 24 hours. The
second group of cells were treated with RIG-I siRNA (50nM) together with Dharmafect
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transfection reagent for 24 hours, and then the medium was changed and the cells were
treated with Dharmafect transfection reagent for another 24 hours. The third group of
cells were treated with Dharmafect transfection reagent for 24 hours, and then the
medium was changed and the cells were treated with 5' -ppp-80nt-random-ssRNA
together with Dharmafect transfection reagent for another 24 hours. The fourth group of
cells were treated with RIG-I siRNA (50nM) together with Dharmafect transfection
reagent for 24 hours, and then the medium was changed and the cells were treated with
5'-ppp-80nt-random-ssRNA together with Dharmafect transfection reagent for another 24
hours. Then total RNA was extracted and RIG-I and IFN-P mRNA level of the cells was
tested via real time PCR. The control RIG-I and IFN-P mRNA level was set as one.
Following the same protocol of RIG-I siRNA and 5'-ppp-80nt-random-ssRNA
transfection, relative cell number of SKOV3-Luc cells was tested via spectrophotometer.
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cells (first group) were treated with Dharmafect transfection reagent only. The second
group of cells were transfected with RIG-I siRNA (50nM). The third group of cells were
transfected with 5' -ppp-80nt-random-ssRNA. The fourth group of cells were transfected
with RIG-I siRNA (50nM) followed by transfection of 5' -ppp-80nt-random-ssRNA.
The RIG-I mRNA level indicated that when cells were transfected with RIG-I
siRNA, there was RIG-I gene knockdown (88% off without 5'-ppp-80nt-random-ssRNA
treatment and 60% off with 5'-ppp-80nt-random-ssRNA treatment). When RIG-I was
knocked down, the immunostimulatory effect of 5 '-ppp-80nt-random-ssRNA was
attenuated (the IFN-P mRNA level decreased) and the cellular toxicity of 5' -ppp-80ntrandom-ssRNA was also attenuated (the relative cell number increased). The results
showed that RIG-I played a role in the recognition of 5'-ppp-ssRNA. The results also
indicated that RIG-I siRNA had no toxicity. However, 5' -ppp-20nt-random-ssRNA had
some toxicity. Both RIG-I siRNA and 5' -ppp-20nt-random-ssRNA were prepared by in
vitro transcription and purified by PAGE. RIG-I siRNA was 27bp 5'-ppp-dsRNA which
had 2nt long 3 '-overhang and 3nt long 5' -overhang. Schlee et al. (2009b) stated that a 3'
overhang at the 5'-triphosphate end decreases RIG-I activity, and any 5'-overhang at the
5'-triphosphate end abolishes RIG-I activity. Maybe RIG-I prefers 5'-ppp-20nt-ssRNA to
5'-ppp-27bp-dsRNA with both 5' and 3' overhangs.
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CHAPTER V
DISCUSSION
The results confirmed the hypothesis that 5'-ppp-ssRNA (2'.: 60nt) is
immunostimulatory and toxic in cancer cells. Whether ssRNAs are immunostimulatory
was controversial in the literature. Hornung et al. (2006) proposed in vitro transcribed 19nt 5' -ppp-ssRNA was immunostimulatory because it could induce strong IFN-a
production in monocytes. However, Schlee et al. (2009b) discovered that chemically
synthetic 24-nt 5' -ppp-ssRNA could not induce interferon-a. Schlee et al. (2009b)
believed that the immunostimulatory effect of 19-nt 5'-ppp-ssRNA in the work of
Hornung et al. (2006) was actually an artifact because in vitro transcribed 5'-ppp-ssRNA
was not pure. During in vitro transcription, RNA-template-dependent RNA transcription
could lead to complementary side products and to double-stranded RNA products that
were originally designed to be single stranded (Cazenave et al., 1994; Triana-Alonso et
al., 1995). Therefore, in vitro transcribed 5'-ppp-ssRNA was contaminated with dsRNA
and 5'-ppp-ssRNA itself was not immunostimulatory (Schlee et al., 2009b). In our study,
PAGE purification was applied to remove dsRNA contamination from in vitro
transcribed ssRNAs and characterization of ssRNAs by gel showed that the purified 5' ppp-ssRNA was very pure. Our results indicated that 5'-ppp-ssRNA (2'.: 60nt) was
immunostimulatory and toxic in SKOV3-Luc cells while 5'-ppp-20nt-ssRNA and 5'-ppp40nt-ssRNA had no immunostimulatory effect and were much less toxic. However, in the
work of Schlee et al. (2009b), 5'-ppp-70nt-ssRNA could not induce IP-10 (Interferon
gamma-induced protein 10) expression in 1205Lu human melanoma cells. The reason for
the contradictory between work of Schlee et al. (2009b) and ours may be the cell line
difference or sequence difference of ssRNAs. The 5 '-ppp-60nt-ssRNA and 5 ' -ppp-80nt-
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ssRNA we used were random sequenced while in the work of Schlee et al. (2009b). 5'ppp-70nt-ssRNA had specific sequence.
The reason for choosing random sequenced ssRNAs in our study is that we
wanted to get a general knowledge of ssRNAs' immunostimulatory effect, regardless of
their sequence. Saito et al. (2008) concluded that AU-rich RNA was more
immunostimulatory than G-rich RNA. When studying random sequenced ssRNAs, more
objective knowledge about the immunostimulatory effect of ssRNAs' 5' -end and length
could be achieved because there was no sequence bias. The results showed that the
immunostimulatory effect and cellular toxicity of ssRNAs increased when the length of
ssRNAs increased. Schmidt et al. (2009) stated that if dsRNAs were too short (S5bp),
they could not induce IFN expression. In our study of ssRNAs, short ssRNAs (S40nt)
could not activate IFN-~. Therefore, enough length is required for the immune activation
of both dsRNA and ssRNA. The reason for the longer ssRNAs' higher
immunostimulatory effect may be that the receptor of ssRNA prefers longer ssRNAs. We
hypothesized that RIG-I was the receptor of ssRNA. RIG-I may prefer longer ssRNAs to
shorter ssRNAs.
In addition to studying the immunostimulatory effect of ssRNAs' length, how the
5' -end of ssRNAs influenced ssRNAs' immunostimulatory effect was studied. Our
results showed that 5'-ppp-ssRNA had a higher immunostimulatory effect and cellular
toxicity than 5'-OH-ssRNA. Hornung et al. (2006) observed that 5' -ppp-ssRNA could
induce IFN-a while 5'-0H-ssRNA could not. Pichlmair et al. (2006) had a similar
opinion. Cui et al. (2008) concluded that the RD (regulatory domain) of RIG-I could bind
to 5'-triphosphate RNA but not to 5'-0H RNA. The RD of RIG-I interacted with 5'-pppdsRNA primarily through extensive electrostatic interactions with the 5'-triphosphate
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group (Lu et al., 2010). We hypothesized that RIG-I was the receptor of ssRNA and RIGI preferred 5' -ppp-ssRNA to 5'-0H-ssRNA. However, when ssRNA was long (such as
145nt-Luc-MS1-ssRNA), the toxicity of ssRNA was much less dependent on the 5'triphosphate group than that of short ssRNA (such as 80nt-random-ssRNA). Maybe
activation of RIG-I was less dependent on 5'-triphosphate group when ssRNA was longer.
Our results indicated that the cellular toxicity of ssRNA increased when the
incubation time increased. The signal transduction of immune and apoptotic pathways
involved lots of signaling proteins (such as VISA, IRF3, CASPASEs) so it took time for
the signaling process from ligand-receptor interaction to final cellular response.
Individual cells were in different states so the time for signaling transduction was
different for every cell. When the incubation time was longer, more cells would undergo
proliferation inhibition and apoptosis and the relative cell number would further decrease.
Our results showed that the cellular toxicity of ssRNA increased when the
concentration of ssRNA increased. The reason may be that if more ssRNAs enter each
cell, more receptors will be activated and the immune signal will be stronger so that more
cells will undergo proliferation inhibition and apoptosis. As a result, the relative cell
number of the cells will decrease when the concentration of ssRN A increases.
The IFN-P mRNA level of the cells treated with ssRNAs showed a similar pattern
with the cellular toxicity of ssRNAs, indicating that cellular toxicity was related with
interferon pathway. However, IFN induction may not be the reason for cellular toxicity.
The cellular toxicity could be observed in a short time after transfection (6h). IfIFN
induction was the reason for cellular toxicity, the cellular toxicity could not be observed
in a short time because IFN-mediated apoptotic pathway was time consuming. Besch et al.
(2009) proposed that RIG-I can activate the mitochondria apoptosis pathway through
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induction ofNoxa. This is a much faster pathway and may explain that the cellular
toxicity of ssRNA showed up in a short time. The IFN-mediated apoptotic pathway may
help the apoptosis in the long time incubation of ssRNA. This may explain the
phenomena that longer time of incubation leaded to higher cellular toxicity.
RIG-I siRNA was utilized in our experiments to study the function of RIG-I in the
recognition of 5' -ppp-ssRNA. The results showed that if RIG-I was knocked down by
RIG-I siRNA, the immunostimulatory effect and cellular toxicity of 5' -ppp-ssRNA were
attenuated. Therefore, RIG-I plays a role in the recognition of 5' -ppp-ssRNA. As known
in the literature, RIG-I is the receptor of 5'-ppp-dsRNA (Yoneyama et al., 2004).
Whether RIG-I can be activated by 5'-ppp-ssRNA was controversial in the literature.
Hornung et al. (2006) stated that RIG-I could be activated by 5'-ppp-ssRNA. Then
Schlee et al. (2009b) believed that 5'-ppp-ssRNA could not activate RIG-I and the
conclusion of Hornung et al. (2006) was wrong because in vitro transcribed 5'-pppssRNA was contaminated with 5' -ppp-dsRNA. In our experiments, 5' -ppp-ssRNA was
very pure (characterized by PAGE) and RIG-I siRNA attenuated the immunostimulatory
effect of 5'-ppp-ssRNA, indicating that RIG-I was involved in the recognition of 5' -pppssRNA. RIG-I may not be the only receptor of 5'-ppp-ssRNA since Karik6 et al. (2004)
discovered that in vitro transcribed 5' -ppp-ssRNA could also activate TLR3 signaling.
Our results also showed that RIG-I siRNA was not toxic. However, the toxicity of 5'ppp-20nt-random-ssRNA could be observed. Both RIG-I siRNA and 5' -ppp-20ntrandom-ssRNA were synthesized by in vitro transcription and purified by PAGE. RIG-I
siRNA was a 27bp 5' -ppp-dsRNA with a 2nt long 3' -overhang and a 3nt long 5'overhang. Schlee et al. (2009b) proposed that a 3' overhang at the 5 '-triphosphate end
decreases RIG-I acitivity, and any 5' -overhang at the 5' -triphosphate end abolishes RIG-I
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activity. The reason for the toxicity difference between RIG-I siRNA and 5'-ppp-20ntrandom-ssRNA may be that RIG-I prefers 5' -ppp-20nt-ssRNA to 5' -ppp-27bp-dsRNA
with both 5' and 3' overhangs.
This work confirmed the hypothesis that 5' -ppp-ssRNA (2:: 60nt) was
immunostimulatory and toxic in cancer cells. Longer 5 '-ppp-ssRNA had higher
immunostimulatory effect and cellular toxicity than shorter 5' -ppp-ssRNA. 5' -pppssRNA induced higher level of immune response and cellular toxicity than 5' -OHssRNA. If the incubation time of ssRNA increased, the cellular toxicity increased. If the
concentration of ssRNA increased, the cellular toxicity increased. RIG-I plays a role in
the recognition of 5' -ppp-ssRNA.
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